Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.
| Revenue (Most Recent Fiscal Year) | $6.85B |
| Net Income (Most Recent Fiscal Year) | $-4.71B |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.09 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.00 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -57.56% |
| Net Margin (Trailing 12 Months) | -68.84% |
| Return on Equity (Trailing 12 Months) | -10.23% |
| Return on Assets (Trailing 12 Months) | -7.70% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.42 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.36 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.04 |
| Inventory Turnover (Trailing 12 Months) | 8.79 |
| Book Value per Share (Most Recent Fiscal Quarter) | $36.33 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.55 |
| Earnings per Share (Most Recent Fiscal Year) | $-12.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-12.41 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 382.88M |
| Free Float | 322.77M |
| Market Capitalization | $41.68B |
| Average Volume (Last 20 Days) | 3.00M |
| Beta (Past 60 Months) | 1.62 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 75.33% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |